Health ❯ Healthcare ❯ Pharmaceuticals

Drug Safety

Mifepristone Contaminated Drugs Fentanyl Contamination Quality Control Medication Recall Product Recall Cough Syrups Contaminated Products Side Effects Contaminated Medications Drug Recalls Counterfeit Medications Adverse Effects Product Recalls Recalls Acetaminophen Counterfeit Drugs Fentanyl Contaminated Medicines Contamination Issues Regulatory Actions GLP-1 Drugs Semaglutide Adverse Events Toxicology Adverse Drug Reactions Black Box Warnings Tirzepatide FDA Regulations Regulatory Compliance Puberty Blockers Cough Syrup Contamination Public Health Contaminated Substances GLP-1 Medications Adulteration Child Health Contamination Cough Syrup Clinical Trials Ranitidine Inhalers Amyloid-Related Imaging Abnormalities Toxicity Opioid Regulations Opioids FDA Actions Clinical Recommendations PFAS and Health Effects Opioid Medications Theft of Medicines Medication Alerts Medication Prohibition Adverse Reactions Duchenne Muscular Dystrophy Unlicensed Drugs Prenatal Medications Consumer Awareness Advertising Standards Chemical Abortion Market Withdrawals Metformina Advertising Compliance Medication Withdrawal REMS Program Good Manufacturing Practices Advisories Cough Syrup Tragedy RSV Treatments Toxic Substances Regulatory Issues Regulatory Inspections Banned Substances Regulatory Review Antibiotics FDA Reviews Illegal Medications Fentanyl Investigation Cannabis Patient Compensation Compensation Ivermectin Contamination Risks Depo-Provera Meningioma Monitoring Systems Insulin Dosing Errors Anticoagulants Compounded Drugs Product Withdrawal Overdose Risks Compounded Medications Compounding Pharmacies Regulatory Warnings GLP-1 Agonists Prescribing Guidelines Sickle Cell Disease Drug Withdrawal Drug Withdrawals

AstraZeneca Withdraws Andexxa From U.S. Market After FDA Says Risks Outweigh Benefits

A confirmatory trial submitted this year showed excess thrombotic events versus usual care.

FDA Adds Brain Tumor Warning to Two Depo‑Provera Injections

FDA Clears First New Oral Gonorrhea Antibiotics in Over 30 Years

EU Regulator Backs Myqorzo for Obstructive Hypertrophic Cardiomyopathy

FDA Opens Safety Review of Infant RSV Antibody Drugs Beyfortus and Enflonsia

FDA Class III Recall Targets 11,136 Bottles of Ziac Over Trace Ezetimibe Contamination

Hawley Pressures FDA Chief as Anti‑Abortion Groups Demand Firing Over Reported Mifepristone Review Delay

Exicure’s Burixafor Delivers About 90% Stem-Cell Mobilization in Phase 2 as Shares Surge

FDA Class II Recall Targets Generic Vyvanse After Dissolution Failures

FDA Class II Recall Issued for 141,984 Bottles of Generic Atorvastatin Over Dissolution Failures

FDA Class II Recall Targets 580,000 Prazosin Bottles for Nitrosamine Overages

Teva, Amerisource Pull 580,000+ Prazosin Bottles as FDA Flags Nitrosamine Contamination

GOP Senators Press FDA Over Generic Abortion Pill Approval

FDA Class II Recall Targets 142,000 Bottles of Ascend’s Atorvastatin

Ascend Recalls 141,984 Bottles of Generic Atorvastatin Over Dissolution Failures

FDA Reapproves GSK’s Blenrep for Multiple Myeloma in Narrow Combination Use

India Cough Syrup Crisis: Sresan Pharma Owner Detained as Tamil Nadu Confirms Toxic Contamination

FDA Creates 'Green List' for GLP-1 Ingredients as WHO Names the Drugs Essential

Sarepta Defies FDA, Keeps Duchenne Gene Therapy on the Market

FDA Restricts Moderna and Novavax COVID-19 Vaccines to Seniors and Vulnerable Groups